A BREATH OF FRESH AIR
It is estimated that around 5.4 million people in the United Kingdom are currently receiving treatment for asthma; a huge cost for the NHS. The launch of a new treatment may help to relieve that burden….
the financial cost to the NHS is estimated to be at least £3 billion every year.
W
Given the fact that asthma affects one in every twelve adults, it’s clear that the financial burden on the NHS is not only unsustainable, but is likely to increase as a result of the growing incidence of the condition.
Now, a new medication for the treatment of adult asthma has been launched in the UK, which has the potential to offer significant cost savings for the NHS.
Luforbec 200/6 (beclometasone 200mcg/formoterol 6mcg) is a certified carbon neutral inhaler which is a pressurised metered dose inhaler (pMDI) for the treatment of adult asthma.
6
scottishpharmacist.com
ith two in every ten people in Scotland currently receiving treatment for asthma in the United Kingdom (UK),
This higher dose option complements the Luforbec 100/6 pMDI and provides a cost- effective asthma treatment range.
Luforbec which has been launched by Lupin Healthcare, the UK-based wholly owned subsidiary of Lupin Limited, is indicated for the treatment of adult asthma where use of an inhaled corticosteroid and long-acting beta2- agonist (ICS/LABA) is appropriate.
Luforbec has the same licensed indications as Fostair 200/6 pMDI, with the same active ingredients, an extra fine formulation and similar device characteristics.
In the twelve months to June 2022, the NHS spent over £241 million on Fostair 100/6 and 200/6 pMDI. Luforbec pMDIs offer a 30 per cent NHS list price saving versus Fostair pMDIs.
It is estimated that, by prescribing Luforbec instead of Fostair could release savings of
approximately £72 million per annum for the NHS: a major saving in this current period of financial strain in the UK.
Following an independent Life Cycle Assessment (LCA) to quantify the carbon footprint of Luforbec 200/6 pMDI, Lupin Healthcare offsets all carbon emissions associated with this pMDI sold in the UK, so, as with the 100/6 pMDI inhaler, it is certified as carbon neutral by Carbon Footprint Ltd through carbon offsetting.
‘We are pleased to make Luforbec 200/6 pMDI available in the UK alongside the already available Luforbec 100/6 pMDI,’ says Ben Ellis, General Manager, Lupin Healthcare. ‘This provides healthcare professionals with a choice of strengths to help optimally manage appropriate asthma patients, and offers the potential to deliver significant NHS savings. At Lupin we are proud that both inhalers are certified as carbon neutral; this is a positive step for Lupin on its sustainability journey.’
THE FINANCIAL COST OF ASTHMA TO THE NHS IS ESTIMATED TO BE AT LEAST £3 BILLION EVERY YEAR
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
